Treatment of Diabetic Neuropathy with Gamma-linolenic Acid.
The Gamma-Linolenic Acid Multicenter Trial Group

This section is compiled by Frank M. Painter, D.C.
Send all comments or additions to:    Frankp@chiro.org

FROM:   Diabetes Care 1993 (Jan);   16 (1):   8–15

Keen H, Payan J, Allawi J, Walker J, Jamal GA, Weir AI,
Henderson LM, Bissessar EA, Watkins PJ, Sampson M, et al

UMDS, London, UK

---

OBJECTIVE:   To compare the effects of placebo and GLA on the course of mild diabetic neuropathy over 1 yr.

RESEARCH DESIGN AND METHODS:   We entered 111 patients with mild diabetic neuropathy from seven centers into a randomized, double-blind, placebo-controlled parallel study of GLA at a dose of 480 mg/day. MNCV, SNAP, CMAP, hot and cold thresholds, sensation, tendon reflexes, and muscle strength were assessed by standard tests in upper and lower limbs.

RESULTS:   For all 16 parameters, the change over 1 yr in response to GLA was more favorable than the change with placebo, and for 13 parameters, the difference was statistically significant. Sex, age, and type of diabetes did not influence the result, but treatment was more effective in relatively well-controlled than in poorly-controlled diabetic patients.

CONCLUSIONS:   GLA had a beneficial effect on the course of diabetic neuropathy.

Return to the DIABETIC NEUROPATHY & EFA Page

Since 1-01-1998